AltheRx™ Pharmaceuticals is a privately held, clinical development company focused on advancing best-in-class compounds with high promise in large unmet markets. Its lead product, Solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS). AltheRx is focused on creating strategic partnerships that complement its development and commercialization capabilities globally for this promising medicine.  Learn more >

MARCH 1, 2012
AltheRx Presents Positive Phase II Results of Solabegron in Overactive Bladder at the European Association of Urology Congress

November 2011
AltheRx Pharmaceuticals featured in Startup "AltheRx Pharmaceuticals Inc. Safe and Highly selective therapy for IBS and OAB"
DOWNLOAD PDF